From November 17 to 20, 2025, MEDICA 2025, the international trade fair for medical equipment hailed as a bellwether for innovation in the medical device sector, kicked off grandly in Düsseldorf, Germany. The grand event gathered thousands of exhibiting enterprises from more than 140 countries and regions around the world, attracting over 80,000 visitors from across the globe to jointly witness and exchange the latest medical technologies and innovative achievements, explore industry development trends, and share valuable experience.
As a provider of rapid sepsis diagnostic solutions, driven by the vision of ensuring that every corner of the world has access to equal and high-quality medical services, Pilot Gene adopts a global perspective and is committed to delivering competitive products and sepsis solutions to the world.
At MEDICA 2025, Pilot Gene showcased its fully automated end-to-end digital PCR solutions developed independently and certified by CE: the rapid sepsis diagnostic solutions based on AP10 and AD3207, which attracted numerous overseas customers to stop by and conduct in-depth exchanges.
Compared with the shortcomings of traditional microbial culture and other molecular detection methods, Pilot Gene's rapid sepsis diagnostic solution based on the digital PCR platform offers remarkable advantages: it effectively shortens the detection time to 3 hours; compared with blood culture, it increases the pathogen detection rate by more than 30%; at the same time, it significantly improves the quality of patient prognostic management. It has become a consensus among many interested distributors consulting about the rapid sepsis diagnostic solution at the booth that innovation drives growth and practice creates value.
With the mission of "Advancing Genetic Technology, Safeguarding Life and Health", Pilot Gene firmly implements the "In China, For Global" strategy. We focus on the field of sepsis, and through continuous R&D and innovation, provide accurate, efficient and convenient rapid diagnostic solutions for medical institutions worldwide. We are committed to using excellent products and services to work with global IVD partners to jointly build a better future for healthcare.
